Results 91 to 100 of about 58,972 (283)
Frontiers in Medicine, 2015 BackgroundEvidence supporting treatment intensification in rheumatoid arthritis is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active rheumatoid arthritis (RA).
Chamaida ePlasencia +10 more
doaj +1 more source
Matching-adjusted indirect comparison:secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis [PDF]
, 2019 Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data
Gandhi, Kunal +12 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis
Frontiers in Pediatrics, 2018 AimAll Irish children with ulcerative colitis (UC) attend the National Centre for Paediatric Gastroenterology at Our Lady’s Children’s Hospital, Crumlin. The aim of this study was to determine the outcomes of children with acute severe ulcerative colitis
Abisoye O. Akintimehin +7 more
doaj +1 more source
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
, 2015 Ofir Elalouf, Ori Elkayam Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel Abstract: The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS).
Elalouf O, Elkayam O
core
Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review
, 2015 The efficacy of infliximab is influenced by individual variability in its pharmacokinetics and pharmacodynamics. Serum infliximab concentrations could therefore be related to the efficacy and tolerance of infliximab, and assist adjustment of treatment ...
Machet, Laurent +5 more
core +1 more source
Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans
Clinical Pharmacology &Therapeutics, EarlyView.Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley +1 more source
Infliximab therapy in pediatric Crohn’s disease: a review
, 2010 Kalyan Ray Parashette1, Raghavendra Charan Makam2, Carmen Cuffari31Department of Pediatrics, University of Illinois at Chicago, Chicago, IL, USA; 2Department of Internal Medicine, Berkshire Medical Center, Pittsfield, MA, USA; 3Division of Pediatric ...
Carmen Cuffari +2 more
core
, 2016 A 51-year-old man was diagnosed with Behçet’s disease in 2001. The patient was resistant to all immunosuppressive therapies. After 6 months of infliximab therapy, he presented to our clinic with pain and blurred vision in his right eye.
Sirel Gür Güngör +6 more
core +1 more source